Loading clinical trials...
Loading clinical trials...
A Phase 2, Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous NVG-2089 in Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Conditions
Interventions
NVG-2089
Locations
1
United States
Nuvig Site
Denton, Texas, United States
Start Date
April 25, 2025
Primary Completion Date
July 31, 2026
Completion Date
July 31, 2026
Last Updated
April 16, 2026
NCT06290141
NCT06858579
NCT06752356
NCT06920004
NCT06637072
NCT07121985
Lead Sponsor
Nuvig Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions